Diviner technology is the first-in-class small molecule inhibitor (SD133) of a novel cancer target (CDH11) increases survival of animals with pancreatic cancer.
Animal challenging, early ADME-T, and PK/PD studies are completed. Advanced preclinical studies are in progress. Diviner technology is funded by the NIH, DoD, NIH SBIR awards and Company partnerships.
STCube Pharmaceuticals Inc.
Copyright © 2022 Diviner Therapeutics - All Rights Reserved.